1-2 of 2
Thomas Eugene, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Patrice Chevallier, MD PhD, Thomas Eugene, MD, Nelly Robillard, Françoise Isnard, MD, Franck E Nicolini, MD PhD, Martine Escoffre-Barbe, MD, Françoise Huguet, Mathilde Hunault, Antoine Marcais, MD, Thierry Guillaume, Jacques Delaunay, MD, Pierre Peterlin, MD, Xavier Thomas, MD PhD, Norbert Ifrah, Simona Lapusan, Caroline bodet-Milin, MD, Alain faivre Chauvet, Claire Le Houerou, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Françoise Kraeber-Bodere, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3708.
https://doi.org/10.1182/blood.V124.21.3708.3708
Published: 2014
Journal Articles

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Patrice Chevallier, MD, PhD, Caroline bodet-Milin, MD, Nelly Robillard, Thomas Eugene, MD, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, MD, Jacques Delaunay, MD, Martine Escoffre-Barbe, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD, Françoise kraeber-Bodere, MD
Journal: Blood
Blood (2013) 122 (21): 3910.
https://doi.org/10.1182/blood.V122.21.3910.3910
Published: 2013